Company
Our mission is to create real hopes
through innovative new drug developments
through innovative new drug developments
History
- HOME
- Company
- History
2017~PRESENT
Growth and Leap of Pinotbio
-
2021
- 06
-
Signed a contract for the joint development of repebody-drug conjugate with
ProEn Therapeutics Co., Ltd.
Signed a contract for the joint development of aptamer-drug conjugate with Aptamer Sciences Co., Ltd.
Signed a contract for the joint development of aptamer-drug conjugate with the UK’s Aptamer Group
Signed a technology transfer contract with AkiraBio, USA, for NTX-301
(for non-cancer drugs)
Completed the phase 1 clinical trial of NTX-101
- 05
-
Acquired the approval of phase 1/2 clinical trial approval for NTX-301
(ovarian cancer and bladder cancer) in Australia
- 03
- Attracted a strategic investment (ST Pharm Co., Ltd.)
- 02
- Started the administration of NTX-301 to clinical patients with blood cancer
-
2020
- 12
- Acquired the domestic phase 1 clinical trial approval for NTX-101
- 11
-
Signed a joint clinical development agreement for NTX-301 in Australia
(Xennials Therapeutics)
Attracted a venture capital investment (Series C, KRW 20 billion)
- 07
- Established Pinotbio North America, Inc., the American branch
- 04
- Changed its company name (Bionetics Co., Ltd. → Pinotbio Co., Ltd.)
- 03
- Selected as an IPO organizer (NH Investment & Securities, KB Securities)
- 02
- Acquired the phase 1/2 clinical trial approval for NTX-301 (blood cancer) in the US
-
2019
- 12
-
Attracted a venture capital investment (Series B, KRW 10 billion)
Completed the phase 1a clinical trial of NTX-301 (solid cancer) in the US
- 06
- Completed the preclinical development of NTX-101
- 04
- Completed the preclinical development of NTX-301 (blood cancer)
- 01
- Started the phase 1a clinical trial of NTX-301 (solid cancer) in the US
-
2018
- 11
- Started the preclinical of NTX-301 (blood cancer)
- 10
-
Acquired the phase 1/2 clinical trial approval for NTX-301 (solid cancer)
in the US (NCI CTEP Program in the US)
Secured the exclusive license for NTX-301
- 09
- Attracted a venture capital investment (Series A, KRW 10,89 billion)
- 02
- Established and acquired corporate laboratory certification
-
2017
- 12
- Started the development of the PINOT-ADC™ platform
- 11
- Attracted a venture capital investment (2nd seed round, KRW 3 billion)
- 06
- Started the preclinical trial of NTX-301 (solid cancer)
- 03
-
Attracted a venture capital investment (1st seed round, KRW 800 million)
Started the preclinical development of NTX-101
- 02
- Established Bionetics Co., Ltd.